Close

VistaGen Therapeutics (VTGN) Granted U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage

May 23, 2018 8:32 AM EDT Send to a Friend
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) today announced that the U.S. Patent and Trademark Office (USPTO) has provided VistaGen with a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login